Filing Flows › Novavax (NVAX) › Licensing, royalties, and other revenue
Novavax (NVAX) Licensing, royalties, and other revenue by quarter
Novavax's Licensing, royalties, and other revenue was $42.6M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 7 quarters it ranged from $37.8M (Q2 2026) to $229M (Q2 2025).
| Quarter | Licensing, royalties, and other revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $42.6M | +13% | -25% |
| Q2 2026 | $37.8M | -61% | -83% |
| Q1 2026 | $97.3M | -10% | +116% |
| Q4 2025 | $108M | +89% | — |
| Q3 2025 | $57.0M | -75% | — |
| Q2 2025 | $229M | +408% | — |
| Q1 2025 | $45.0M | — | — |
Q3 2026 at a glance
Novavax, Q3 2026: revenue $68.3M (-3% year over year), operating margin -45.8%, net loss $31.4M, operating cash flow −$94.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Novavax's Licensing, royalties, and other revenue?
Novavax's Licensing, royalties, and other revenue was $42.6M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Novavax's Licensing, royalties, and other revenue changed?
Over the last 7 quarters it ranged from $37.8M (Q2 2026) to $229M (Q2 2025).